Biotech Values

[Mufaso]

Participants taking Novo Nordisk’s experimental weight loss treatment amycretin lost 13% of their weight over 12 weeks in an early stage clinical trial, the company revealed at an investor event.

Amycretin is an oral medicine that targets the same GLP-1 hormone as other weight loss drugs like Novo’s Wegovy and Lilly’s Zepbound, as well as stimulating another hormone, amylin, which regulates hunger.

The results, which have not been published or subject to external scientific scrutiny, exceed weight loss from its blockbuster drug Wegovy, which was around 6% at 12 weeks.

Novo said amycretin appeared to be safe and well-tolerated and had a similar side effect profile to its other medicines in the field like semaglutide, the injectable GLP-1 drug sold as Ozempic for diabetes and Wegovy for weight loss.

While stressing that the trial was small, Novo’s head of development Martin Lange Holst said the promising results justify further research into the pill.

https://www.forbes.com/sites/roberthart/2024/03/07/novo-nordisks-new-obesity-pill-beats-wegovy-in-early-trial/?sh=6108df0d456e